Annals of internal medicine

Cancer risk linked to glucagon-like peptide-1 receptor activators and combined activators: A systematic review and meta-analysis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Disclosures: Disclosure forms are available with the article online.
PubMed

Related papers

Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Oct '25
Tirzepatide treatment for adults with obesity
cited by 3 papers
systematic review
Apr '25
Real-world use, benefits, and side effects of new weight-loss treatments based on GLP-1 receptor activators
top 5% journal
cited by 98 papers
journal article
Nov '25
Effectiveness and safety of glucagon-like peptide 1 drugs for all health outcomes in type 2 diabetes
top 5% journal
cited by 2 papers
systematic review
Jul '24
Glucagon-Like Peptide 1 Receptor Agonists and Risk of 13 Obesity-Related Cancers in People with Type 2 Diabetes
top 2% journal
cited by 233 papers
research support, n.i.h., extramural
Oct '25
Liraglutide treatment for adults with obesity
cited by 2 papers
systematic review
Jun '25
Digestive Side Effects of Drugs That Activate Glucagon-Like Peptide-1 Receptors: A Comprehensive Review and Analysis
top 1% journal
cited by 30 papers
systematic review
Aug '25
Comparison of Medicines for Adults with Type 2 Diabetes
top 5% journal
cited by 25 papers
systematic review
Oct '25
Semaglutide treatment for adults with obesity
cited by 6 papers
systematic review
Jan '21
Comparing SGLT-2 inhibitors and GLP-1 receptor agonists for type 2 diabetes: review and analysis of clinical trials
top 5% journal
cited by 520 papers
systematic review

Featured in

GLP-1 TherapiesGLP-1 TherapiesIssue #15
Analysis of 2.2 million patients finds GLP-1 drugs reduced liver cancer risk by 42%
↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief